ELEV vs. NKTX, ADCT, ENTA, ACTU, NVCT, TIL, LXEO, ADAP, STRO, and SLN
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Nkarta (NKTX), ADC Therapeutics (ADCT), Enanta Pharmaceuticals (ENTA), Actuate Therapeutics (ACTU), Nuvectis Pharma (NVCT), Instil Bio (TIL), Lexeo Therapeutics (LXEO), Adaptimmune Therapeutics (ADAP), Sutro Biopharma (STRO), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry.
Elevation Oncology vs.
Nkarta (NASDAQ:NKTX) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
Nkarta received 25 more outperform votes than Elevation Oncology when rated by MarketBeat users. Likewise, 76.92% of users gave Nkarta an outperform vote while only 76.09% of users gave Elevation Oncology an outperform vote.
Nkarta's return on equity of -27.13% beat Elevation Oncology's return on equity.
Nkarta currently has a consensus target price of $15.00, suggesting a potential upside of 631.71%. Elevation Oncology has a consensus target price of $7.20, suggesting a potential upside of 1,085.38%. Given Elevation Oncology's higher probable upside, analysts clearly believe Elevation Oncology is more favorable than Nkarta.
80.5% of Nkarta shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 8.7% of Nkarta shares are owned by company insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Nkarta had 8 more articles in the media than Elevation Oncology. MarketBeat recorded 8 mentions for Nkarta and 0 mentions for Elevation Oncology. Nkarta's average media sentiment score of 0.98 beat Elevation Oncology's score of 0.00 indicating that Nkarta is being referred to more favorably in the media.
Nkarta is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks.
Nkarta has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
Summary
Nkarta beats Elevation Oncology on 9 of the 16 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:ELEV) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ELEV Stock Alerts